Record-Breaking Sales Growth
Product sales during the first quarter of 2025 increased by 11% or $810,000 over the first quarter of 2024, reaching a record $8.1 million. This surpassed the previous record set in the fourth quarter of 2024.
Gross Margin Improvement
The gross margin increased to 42% in Q1 2025, up from 37% in Q4 2024, indicating operational improvements and higher production efficiency.
Significant Adjusted EBITDA Growth
Adjusted EBITDA improved significantly to $2.3 million in Q1 2025, compared to $458,000 in Q1 2024.
Successful Production Capacity Expansion
ImmuCell's production capacity increased to over $30 million annually, supporting future growth and reducing backlog from $4.4 million to $3.4 million.
First Defense Product Line Expansion
Introduction of new product formats for First Defense, expanding its use and market appeal.
No Recent Contamination Events
No contamination events reported for over a year, indicating improved production processes.